Medical Companies in Europe

Boneprox provides services and products based on AI, machine learning and secure and efficient communication to the dental and health sector. Enabling clinics, dentists and doctors to become more efficient in sending, receiving, analyzing and diagnosing images and patients. In addition to this, Boneprox invests heavily in R&D and A.I to improve and streamline daily diagnostics as well as connect dental care and healthcare by finding patients at risk for systemic diseases based on dental X-ray images. Today, we have become the leader in digitalization within the industry. Boneprox has also developed Konekta, a digital specialist clinic that increases the availability of specialist competence and secures communication between specialists, clinics, dentists, and colleagues. The platform makes it possible to send digital referrals and questions to our connected specialists. With Konekta, our specialists are available as an extra resource and complement for the therapist when you need guidance from the right expertise. Today, it can take up to 15 months to get help from a specialist – Konekta gives an answer the same day. From innovation to reality!

Aligned (www.aligned.ch) provides Aligned Elements, an Application Lifecycle Management (ALM) software for Medical Device development. We assist our clients in developing, manufacture and market regulatory compliant products within shorter timeframes, to lower costs and with higher confidence. At Aligned, we believe that management of product and project documentation of regulatory compliant products shall be efficient and pragmatic. We advocate an apporach that allows your development team to focus on innovation instead of administration. Many of clients develop and manage medical products, regulated by norms such as the FDA QSR regulations in the USA or by the In Vitro Diagnostic Directives (IVD-D) in Europe. It is the special needs and circumstances which drive such projects that also shape our own portfolio. We strive to build value that last and therefore stay deeply involved with the undertakings of our clients until we are sure that sustainable results are achieved.

MedQAIR provides end-to-end regulatory and quality compliance support for medical devices, IVDs, and AI-enabled health technologies across global markets, including the EU (EU MDR, IVDR), US (FDA), and Canada (Health Canada). We support manufacturers across both pre-market and post-market phases, ensuring efficient market access and continuous compliance throughout the product lifecycle. 𝗖𝗼𝗿𝗲 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 Authorised Representative (AR) | PRRC | Regulatory Strategy & Technical Documentation | EUDAMED & UDI Management | Vigilance & Post-Market Surveillance | AI & Software Compliance To simplify compliance between Economic Operators / medical device partners, MedQAIR developed MDIS (Medical Device Information System) - a secure, ISO 27001-certified platform that: - Tracks Basic UDI & UDI-DIs - Automates EUDAMED registrations and updates - Enables secure sharing of technical documentation - Supports vigilance reporting and audit-ready traceability Together, our expert consulting and MDIS platform help manufacturers maintain compliance, ensure transparency, and respond rapidly to post-market obligations.

We provide the AI tools for the analysis of brain function in intensive care. CERENION C-TREND™ offers the first truly objective and practical method to obtain reliable information on the condition and function of the brain. The clinically validated technology can be integrated into EEG-measurement devices and patient monitors as a software feature. CERENION C-TREND™ is a medical-grade software solution that works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The result is a set of easy parameters that aid medical professionals in clinical decision making. The patented technology has the potential of improving both the quality and the cost of intensive care. Cerenion™, Cerenion C-Trend™, C-Trend™ are trademarks of Cerenion Oy. Cerenion technology is covered by Intellectual Property Rights. All rights reserved. © Cerenion Oy 2017.

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

This is Higo® – a breakthrough telemedical solution, that introduces a new definition of "medical appointment". Doctors no longer have to take patients in the office, because – thanks to Higo® – patients can collect data about their health themselves: measure temperature, listen to the heart and lungs, take pictures of the throat, ear and skin. Afterwards, Higo sends the data to the doctor who makes the diagnosis.

Heart Force is about to break new ground in the early detection of heart disease. Through the assessment of the cardiac performance with a new unique technology we are able to detect coronary artery diseases at an early stage. Our Cardiac Performance Metrics represent a new capability for analyzing cardiac timing, rhythm and strength not found in the personal monitoring and screening space. Cardiovascular disease (CVD) is the number one cause of death globally (Source: WHO). Early detection is the missing key to successfully combat CVD, but difficult to achieve; CVD often does not show any symptoms. Through Heart Force it will be possible to self monitor the overall heart health and spend a life with more clarity concerning the overall heart health.

HeartBeat.bio is a VC funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies. Our core technology is based on the world-wide first, self-organizing cardiac organoids (Cardioids) which resemble the human physiology of a human heart chamber in a way that allows for the cost-efficient and large scale in-vitro analysis of crucial clinical parameters associated with various cardiac diseases. The Cardioid-based screening platform has the potential to radically change the current cardiovascular drug discovery paradigm.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

𝐝𝐨𝐜𝐭𝐨𝐫𝐚𝐧𝐲𝐭𝐢𝐦𝐞 is the #1 health tech multinational company to search for medical services. Founded in 2012 we are already operating in 6 countries. ▪️ We are an innovative platform that improves all functional/management matters of healthcare, like finding the right doctor for a user, booking appointments, creating and keeping a medical file etc. ▪️ Everyday we help hundreds of people to find the right doctor, the medical examination they need and book an online appointment with the selected doctor immediately. Setting as our main objective to respond to one simple need: 𝐭𝐨 𝐜𝐮𝐫𝐞 𝐚𝐧𝐝 𝐜𝐚𝐫𝐞, to offer anyone the security and peace of mind, when it comes to health related issues. ▪️ 𝐝𝐨𝐜𝐭𝐨𝐫𝐚𝐧𝐲𝐭𝐢𝐦𝐞 is free for patients and available in: - Greece - Belgium - Cyprus - Mexico - Argentina - Brazil - Peru - Ecuador - Colombia with many more soon to come.

At doctorly we are creating the future of digital health care. Our vision: 'Enabling people to live healthier lives'. We believe that technology, hand in hand with medical professionals, can create a truly modern and exponentially more effective approach to health care. With our unique b2b2c model, doctorly provides all of the digital technology, tools, and support, via a single system, for a doctor to efficiently and digitally manage their practice, and to engage with their patients like never before. We are also enabling patients to access, control and understand their own health records and data. Backed by some of the best investors in the world, the doctorly team is a wonderful mix of serial tech-entrepreneurs, amazing engineers & medical experts. We're hiring: https://doctorlycareer.kenjo.io/

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

We strive to always deliver exceptional patient care with compassion, respect and integrity. Our promise at 108 Harley Street is to always listen. We understand that each patient’s journey is unique. In order to satisfy the individual needs, values and medical requirements of each of our patients, our staff endeavour to provide tailored and personalised care.

Ability Case Management coordinates person-centred rehabilitation and support for individuals with Acquired Brain Injury, Spinal Cord Injury and/or Orthopaedic Injury. We are committed to listening to our clients and their family members to provide a comprehensive assessment and intervention plan tailored to individual needs. Working in collaboration with approved service providers we proactively lead the rehabilitation and support process in partnership with clients and their family members. We are resilient and persistent, breaking down barriers in our determination to achieve the best possible outcomes for our clients. Ability Case Management is a highly organised, diligent and resourceful service with the goal of helping individuals reach their full potential following injury.

Ada is a global health company created by doctors to improve human health by transforming knowledge into better outcomes. Ada is the world's most popular symptom assessment app, with 10 million users and 25 million completed assessments. Every three seconds, someone turns to Ada for personal health guidance. Our powerful enterprise solutions help partners inform health decisions, triage to appropriate care, and reduce avoidable costs. We work with healthcare systems and providers, insurers, payers and commissioners, life sciences, employers, governments, and non-profits.

Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development.

IOMED has developed a Natural Language Processing tool that allows hospitals to structure their information identifying clinically relevant variables from medical notes and structuring them into datasets, which can then be easily queried. Thanks to this data structuration, professionals and researchers from the hospitals can access to the information stored in their facilities more quickly thus accelerating patient recruitment by reducing the time invested in this process. At the same time, it allows hospitals to improve the quality of their services. Overall, we accelerate Clinical Research through the use of Artificial Intelligence, allowing access to structured RWD from hospital medical records and considerably optimizing your studies in time and access to patient volume. Finally, data protection is IOMED’s priority and we work to ensure a safe and secure environment: each hospital decides and authorizes all data uses and participation in projects, the data is stored entirely within the hospital, and always following international and Spanish legislation.

Jutro Medical’s advanced telemedicine platform and app offer virtual consultations, prescriptions, referrals, lab results and the ability to request medical leave online for less complex cases. Yet when more direct, more detailed or more complex care is required, patients can be seen by a Jutro Medical practitioner – typically the practitioner they’ve been liaising with virtually to maintain a continuity of care – at the startup’s proprietary clinics. All on the same day and all without waiting times, or having to constantly repeat their medical history and care needs with various people. This improves the experience for patients, gets them access to the best care possible, all while making doctors more productive.

Kaspard is a non-intrusive system that in case of fall or too long bed exits provides real-time information to nurses in institutions.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier. Awards: Winner: Health Category at the Future Planet Awards 2019 Winner: Best New Concept or Innovation at the 2018 Yahoo Sports Technology Awards Winner: 2018 CES Innovation Award Winner: Start-Up of the Year at the 2018 Digital DNA Awards Winner: Start-Up World Cup Northern Ireland Winner 2018 Winner: Randox Health Weight Management Product of the Year 2018 Winner: Business Eye Small Business Awards Healthcare Business of the Year 2018 Winner: Innovative Business of the Year at the BEFTA 2018 awards Placed 3rd at 2018 CES Last Gadget Standing Finalist for Med Tech Innovator Award Finalist in the Best Investment in the Disruptive Tech category at the UK Business Angel Investment Awards 2019

B-Secur is a heart health technology company. Founded in Belfast, Northern Ireland, we are on a mission to save and improve millions of lives each year by advancing heart health technology that brings greater clarity to EKG interpretation with better data and deeper insights. We spent many years immersed in deep scientific research in EKG biometric security. This led us on a unique journey to develop heart health technology and drive better health outcomes for future generations. Covid-19 has accelerated the pace of our innovation as the world of medical technology and consumer devices converge. We have created HeartKey® 2.0, a suite of powerful EKG algorithms and analytics that enhances signal clarity, reduces signal noise, and delivers FDA-cleared health data with actionable wellness insights. We partner with world-leading technology companies reducing time to market for next generation medical and consumer devices and platforms. Our expertise in EKG coupled with deep experience in hardware, software and science enables our partners to tackle the fundamental healthcare issues of today.

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We’re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be.

Offer hyper-personalized products the easy way. Your product personalization platform. A unique customer experience, efficient order management, and a seamless connection to manufacturing. Twikit is a technology company with a sharp focus on mass customization and digital manufacturing for brands and industries across all continents. The company offers a cloud suite of SaaS products that enables an end-to-end mass customization workflow for automotive, orthoses, protective and sports gear, interior and construction, and lifestyle and wellness. With Twikit’s proprietary technology, the company sets new standards for how brands and industries design and create products: customizable, on-demand, and digital. The company was founded in 2013 and is headquartered in Antwerp, Belgium, with offices in the U.S. and China. Twikit

ImageBiopsy Lab (IB Lab) is a leading digital health scale-up, providing AI-supported expertise for orthopedic surgery, musculoskeletal (MSK) radiology and affected patients alike. We are a group of physicians, software engineers and entrepreneurs, passionate about our cause to find optimal solutions to complex medical needs through the latest technological innovations. Our vision is to become the One-Stop-Shop for musculoskeletal imaging intelligence, enabling new medical standards for 1.7B patients being affected. What differentiates IB Lab from other AI-supported medical companies is our clear focus to go beyond diagnostics, turning large amounts of unstructured imaging data into meaningful evidence.

Innovative polish company offering monitoring wristbands and telemedine platform to hospitals, institutions, idividuals SiDLY initiates the development of medical telematics in Poland and Europe. SiDLY sp.z o.o. as one of the first organizations, deal comprehensively with medical diagnostics from the distance, starting from the search of areas requiring initiating telematics solutions through design, testing and constructing of both- devices and systems, and the dedicated application. SiDLY team, consists of the representatives of technology, medicine and science. The products of SiDLY improve the work of clinics and houses of Social Welfare. They also enable a remote medical diagnostics for individual costumers. Telemedical platform with wristbands is implemented in hospitals, including contagious departures.

Talking Medicines is changing the way that the world markets drugs through data science. As the world’s first company dedicated to uncovering the true patient voice from public sources, Talking Medicines’ aim is the gold standard for real-world patient intelligence. Powered by artificial intelligence, its SaaS solution PatientMetRx® turns unstructured patient feedback from social media into actionable insights - helping drug marketers become more efficient and effective at reaching patients with impactful campaigns, delivering better health outcomes for all.

Clear Surgical, is a new medical device company established in 2013 to design, manufacture and sell innovative medical devices for use in surgery. Products include the only disposable self-retaining illuminated retractor for improving the field of light in surgical cavities and also the cannulated reduction forceps that act as a universal guidance system for use in treating fractures for orthopaedic patients. The Cannulated Reduction Forceps facilitate the placement of equipment and implants such as surgical screws, suture systems and K-wires with considerable accuracy and ease. The Oplight is designed for use by medical professionals carrying out open cavity surgery and will provide retraction for surgical incision while using small, in-built LED technology to illuminate the part of the body being operated upon.

Oncomfort Digital Sedation™ is a non-pharmacological therapy for relieving patients’ pain and anxiety before, during and after medical procedures. This digital therapy combines clinical hypnosis and integrative therapeutic techniques through Virtual Reality.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Atlantic Instrument For Research (AI4R) is the world leader in digital real-time autoradiography, a new-generation imaging solutions for preclinical studies. Our company has designed a new autoradiograph: the BeaQuant. Our device uses an innovative technology (gaz detection) to give researchers a quantitative mapping of radioactivity in a sample (alpha and beta radioisotopes) . Users will experience the highest resolution in the market for autoradiographic analysis, shorter acquisition time, complete safety and unique versatility (with features such as: QWBA or dual-isotope analysis). The BeaQuant is the perfect tool to establish in vitro–in vivo correlation. If you are interested in learning more about our technology, please feel free to visit our website and contact us!

Aktiia – Bringing blood pressure monitoring to daily life Aktiia was founded in 2018 to commercialize its proprietary cuffless optical Blood Pressure Monitoring technology (oBPM™) in order to contribute to the prevention of high blood pressure, to save lives and to help reduce healthcare costs worldwide. aktiia is headquartered in Neuchatel (Switzerland) with offices opening up in Zurich (Switzerland) and the USA.

ALEVA is 👉THE COMPANY THAT INTRODUCED Directional Deep Brain Stimulation in Neuromodulation treatments and our clinically proven technology has set the industry standard for directional leads* Today we are 👉A SOLID COMPANY that following directSTIM™'s CE marking have started our commercial journey by partnering with the most important neurological clinics in Germany, with the goal to soon reach the most relevant European markets. We understand that if we want to help OUR CUSTOMERS, overcome their challenges, we need to 👉COMBINE SPECIALISATION with the 👉COMMITMENT TO BE RESPONSIVE to the everyday new challenges they experience. This is the attitude you will find in every ALEVA employee and sales representative who will be in contact with you. We are the 👉ONLY EUROPEAN COMPANY that designs, manufactures, and commercialises DBS devices for the treatment of Parkinson’s disease and essential tremor. Our production and R&D headquarters based in Switzerland complies to the highest quality standard for the highest safety of patients worldwide. Our A VISIONARY PROJECT SUSTAINED BY SOLID FOUNDATIONS: 👉a new group of investors that will sustain the completion of OUR PROJECT 👉a reinforced executive team who is complementing the existing successful group to partner with Neurosurgeons and Neurologists in the effective deployment of our Vision. *May 28, 2014 http://doi.org/10.1093/brain/awu102.

At Alex Therapeutics, we design and develop CE-certified Digital Therapeutics (DTx) products. We’re a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artificial Intelligence to provide patients with highly personalized and effective care. The Alex Platform allows for the easy development of new products, and we see incredible potential in future verticals such as obesity, depression, oncology, and more. We’re always looking for great partners and co-workers. Please send us an email at partner@alextherapeutics.com to get in touch.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

With Attolight, Cathodoluminescence (CL) is now available in a streamlined system which integrates CL with both light (LM) and electron microscopy (EM): what was a challenging experiment in the past, often done on klunky, home-made devices can now be done easily and efficiently. Attolight is now changing the landscape: its innovative approach brings nanometer resolution as well as pico-second timing for time-resolved studies, regardless of the wavelengths used. While any material that emits light under electron irradiation can be studied by CL, it is particularly valuable in material studies of semi-conductor materials, phosphor, ceramic, rock and glass. Combining LM, EM with hyperspectral imaging, Attolight’s solution reveals ultra-trace impurities and crystallographic defects not visible using other imaging modalities. Attolight "New Cathodoluminescence" solutions support the state-of-the -art research and developments in LEDs, Solar Cells, High Mobility Transitors, new opto-electronical devices, nano-structured semiconductors.

BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com

biosurfit develops innovative medical diagnostic solutions in order to improve the performance and outcomes of physicians, by providing real-time and accurate results of blood analysis. Its core product is spinit®, a user-friendly instrument that combined with a disposable disc uses one small drop of blood to give precise results within minutes for multi-parameter test panels. spinit® will soon have the potential to perform a vast majority of blood tests combining cell and immuno-based diagnostics, with integrated sample preparation into the disposable disc. biosurfit will continuously develop different tests for the spinit® platform, addressing the physicians' needs.

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.

The British Nuclear Medicine Society (BNMS) is the only independent forum devoted to all aspects of Nuclear Medicine. Established in 1966 as the Nuclear Medicine Society, its membership includes the clinicians dealing with the medical speciality, clinical scientists, radiopharmacists, other scientists, nuclear medicine technologists and nurses

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. An important challenge for any therapeutics company using machine learning is “ground-truth data,” or information known to be true. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems. The platform then requests new experiments to improve its predictive ability, cutting through an otherwise intractable combinatorial space.

Endomag is a medical technology company devoted to improving the global standard of cancer care. Our Sentimag® probe, Magseed® marker and Magtrace® lymphatic mapping agent are already in use by many of the world’s leading physicians and cancer centres. Our goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. We’ve helped tens of thousands of women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), we continue to develop our unique clinical platform from our headquarters in Cambridge, United Kingdom.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

EUCODIS Bioscience is a leading provider of novel industrial enzymes, with customers in the pharmaceutical, biotechnology, diagnostics, and other industries worldwide. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions. In addition, EUCODIS Bioscience provides services ranging from enzyme engineering to process development as well as protein manufacturing according to our customers' individual specifications. EUCODIS Bioscience provides customized services in recombinant protein and enzyme production by covering the whole spectrum of bioprocess development up to industrial-scale manufacture of your target proteins under ISO9001. Our headquarters and main laboratories are located at the Campus Vienna Biocenter, Austria’s largest Biotech and University cluster.

Axiles Bionics is a new Brussels spin-off, from de Vrije Universiteit Brussel, developing the newest generation robotic ankle-foot prosthesis. Our mission is to improve the quality of life of amputees by bringing this newest bionic foot to the market.

We specialize in the creation of AI-powered imaging biomarkers to enable precision medicine for better treatment decisions. Since launching as a spin-out from the University of Oxford in 2010, we have developed award-winning, AI-powered imaging biomarkers and software solutions, assisting physicians across the world to make better life-saving decisions.

Personal MedSystems is a pioneer in digital health. The company develops mobile diagnostic devices to enable the delivery of mobile healthcare. The CardioSecur product portfolio comprises mobile 12-lead ECG technologies that allow both patients and physicians to perform an instant heart check wherever they are. CardioSecur is the first and only mobile 22-lead ECG system with only 4 electrodes for physicians and patients. As easy to use personalized heart check for iPad/iPhone/iPod touch it enables patients at all times to gain certainty about their hearts‘ activity. Its instant evaluation of ischemic and rhythmic disorders and resulting direct recommendation allow patients to act swiftly and appropriately. Physicians do have the unique opportunity to perform precise diagnosis based on 22-lead ECG data from the moment of the cardiac event. So far an often insufficiently screened area.

Cardisio aims to sharply reduce unnecessary deaths, impaired quality of life, and medical expenses by providing an early heart disease screening to more people, more easily and with more accurate results. With these intentions, we developed Cardisiography, an AI-based 3D-vectorcardiography that allows for easy detection of pathological signs of arterial and structural heart diseases. Our innovative technology is much more exact than conventional first-line diagnostics and reaches a sensitivity of more than 90%. For more information about our product and company, please visit: https://cardis.io

CUREosity is a multiple international award-winning Med-Tec company located in Düsseldorf, Germany, that is changing rehabilitation by developing innovative therapy concepts. With our vision to revolutionize traditional rehabilitation we develop VR-based therapy applications and games to help people with neurological and mental disabilities. Change the world and become part of a unique collaboration between scientists, medical doctors, therapists, software developers and game designers. Together we develop completely new motion therapy systems - immersive instead of invasive. Impairments we aim to heal include stroke, craniocerebral trauma, MS, cerebral palsy, Parkinson's, paraplegia as well as dementia, depression, anxiety and pain therapy. With CUREO we developed our first smart software solution for innovative VR therapy that can be used immediately in any clinic. Grow with us! Give your daily work a deeper meaning and support us with your talent to help people with neurological and psychological disabilities. You can also benefit from being on board by growing with us personally and professionally, revolutionizing traditional rehabilitation. Became curious? Then follow or contact us on LinkedIn, visit our website and apply at jobs@cureosity.de!